Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3070
Name malignant glioma
Definition A cell type cancer that has_material_basis_in glial cells and is located in brain or located in spine.
Source DiseaseOntology.org
Alt Ids DOID:2627
Path disease disease of cellular proliferation cancer cell type cancer malignant glioma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Plicamycin malignant glioma not applicable detail...
IDH1 R132C AGI-5198 malignant glioma sensitive detail...
IDH1 R132H AGI-5198 malignant glioma sensitive detail...
Unknown unknown MRX34 malignant glioma not applicable detail...
Unknown unknown Sunitinib malignant glioma not applicable detail...
FGFR3 - TACC3 PD173074 malignant glioma sensitive detail...
FGFR1 - TACC1 PD173074 malignant glioma sensitive detail...
FGFR3 - TACC3 AZD4547 malignant glioma sensitive detail...
FGFR1 - TACC1 AZD4547 malignant glioma sensitive detail...
FGFR1 - TACC1 Infigratinib malignant glioma sensitive detail...
FGFR3 - TACC3 Infigratinib malignant glioma sensitive detail...
Unknown unknown PQ401 malignant glioma not applicable detail...
FGFR3 - TACC3 Erdafitinib malignant glioma sensitive detail...
HRAS G12V SF1126 malignant glioma sensitive detail...
IDH1 mutant N/A malignant glioma not applicable detail...
ATRX loss IDH1 mut Gemcitabine + Radiotherapy malignant glioma predicted - sensitive detail...
Unknown unknown GDC-0084 malignant glioma not applicable detail...
Unknown unknown ADDA 5 malignant glioma not applicable detail...
BRAF V600E Everolimus + Selumetinib malignant glioma predicted - sensitive detail...
BRAF V600E PLX4720 + Selumetinib malignant glioma predicted - sensitive detail...
BRAF V600E Everolimus + PLX4720 malignant glioma predicted - sensitive detail...
BRAF wild-type Everolimus + Selumetinib malignant glioma predicted - sensitive detail...
IDH1 mutant Ivosidenib malignant glioma sensitive detail...
Unknown unknown Everolimus malignant glioma not applicable detail...
Unknown unknown Bevacizumab + Marizomib malignant glioma not applicable detail...
Unknown unknown Toca 511 + Toca FC malignant glioma not applicable detail...
IDH1 R132H BPTES malignant glioma sensitive detail...
IDH1 R132H Talazoparib malignant glioma sensitive detail...
IDH1 R132C Talazoparib malignant glioma sensitive detail...
Unknown unknown AdV-tk + Valacyclovir malignant glioma not applicable detail...
Unknown unknown PV1019 + Radiotherapy malignant glioma not applicable detail...
IDH2 R140Q AG-881 malignant glioma predicted - sensitive detail...
IDH1 R132H AG-881 malignant glioma predicted - sensitive detail...
Unknown unknown RES-529 malignant glioma not applicable detail...
IDH2 mutant N/A malignant glioma not applicable detail...
IDH1 R132H N/A malignant glioma not applicable detail...
IDH1 wild-type N/A malignant glioma not applicable detail...
IDH2 wild-type N/A malignant glioma not applicable detail...
ATRX mutant N/A malignant glioma not applicable detail...
Unknown unknown DNX-2401 malignant glioma not applicable detail...
Unknown unknown NEO212 malignant glioma not applicable detail...
Unknown unknown Bevacizumab + MEDI3617 malignant glioma not applicable detail...
BRAF V600E Vemurafenib malignant glioma predicted - sensitive detail...
Unknown unknown NEO214 malignant glioma not applicable detail...
BRAF V600X Dabrafenib malignant glioma predicted - sensitive detail...
ATRX S458* Adavosertib malignant glioma sensitive detail...
ATRX R781* Adavosertib malignant glioma sensitive detail...
PIK3CA R88Q Buparlisib + Selumetinib malignant glioma sensitive detail...
PIK3CA E542K Buparlisib + Selumetinib malignant glioma sensitive detail...
PIK3CA H1047R Buparlisib + Selumetinib malignant glioma sensitive detail...
HRAS mut PIK3CA M1043V Buparlisib + Selumetinib malignant glioma sensitive detail...
HRAS mut PIK3CA R88Q Buparlisib + Selumetinib malignant glioma sensitive detail...
HRAS mut PIK3CA E542K Buparlisib + Selumetinib malignant glioma sensitive detail...
IDH1 mutant AG-881 malignant glioma predicted - sensitive detail...
IDH2 mutant AG-881 malignant glioma predicted - sensitive detail...
EML4 - NTRK3 Crizotinib malignant glioma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00876993 Phase I Bevacizumab + Irinotecan + Temozolomide Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors Completed
NCT00879437 Phase II Bevacizumab Valproic acid Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas Active, not recruiting
NCT01052363 Phase I Bevacizumab + Fosbretabulin OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas Withdrawn
NCT01089101 Phase Ib/II Selumetinib Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma Recruiting
NCT01107522 Phase I Carboxyamidotriazole Orotate + Temozolomide Carboxyamidotriazole Orotate Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas Unknown status
NCT01130077 Phase I Poly ICLC A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas Recruiting
NCT01156584 Phase I Toca 511 + Toca FC A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma Completed
NCT01188096 Phase II Poly ICLC A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas Unknown status
NCT01266031 Phase Ib/II Bevacizumab + Vorinostat Bevacizumab Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma Completed
NCT01331135 Phase I Sirolimus Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Completed
NCT01386580 Phase Ib/II 2B3-101 2B3-101 + Trastuzumab An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. Completed
NCT01392209 Phase I Bevacizumab Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma Completed
NCT01434602 Phase Ib/II Everolimus + Sorafenib Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas Recruiting
NCT01435395 Phase I Bevacizumab + Bortezomib + Temozolomide Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme Completed
NCT01478178 Phase Ib/II VAL-083 Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma or Progressive Secondary Brain Tumor Completed
NCT01478321 Phase II Bevacizumab + Temozolomide Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas Terminated
NCT01547546 Phase I GDC-0084 A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma Completed
NCT01644773 Phase I Crizotinib + Dasatinib Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) Completed
NCT01648348 Phase Ib/II Carotuximab Bevacizumab Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Completed
NCT01661400 Phase I Cyclophosphamide Thalidomide Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors Recruiting
NCT01677741 Phase I Dabrafenib A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects Active, not recruiting
NCT01743950 Phase II Bevacizumab A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab Recruiting
NCT01748149 Phase I Vemurafenib Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas Active, not recruiting
NCT01817751 Phase II Valproic acid Sorafenib Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent High-Grade Glioma Active, not recruiting
NCT01903330 Phase II Bevacizumab Cyclophosphamide Sargramostim ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme Recruiting
NCT01925573 Phase I Bevacizumab NOVOTTF-100A+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344) Active, not recruiting
NCT01954030 Phase Ib/II Bevacizumab Carboxyamidotriazole Orotate Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure Terminated
NCT01977677 Phase Ib/II Temozolomide Plerixafor Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Completed
NCT01985256 Phase I Toca 511 Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor Completed
NCT01989052 Phase Ib/II Lomustine Carboxyamidotriazole Orotate Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma Terminated
NCT02017717 Phase III Nivolumab Bevacizumab Ipilimumab + Nivolumab A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143) Active, not recruiting
NCT02023905 Phase II Temozolomide Everolimus Everolimus With and Without Temozolomide in Adult Low Grade Glioma Active, not recruiting
NCT02026271 Phase I Ad-RTS-IL-12 plus AL A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma Active, not recruiting
NCT02034110 Phase II Dabrafenib + Trametinib Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Active, not recruiting
NCT02052648 Phase Ib/II Temozolomide Indoximod Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors Completed
NCT02100891 Phase II Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors Recruiting
NCT02101905 Phase I Lapatinib Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma Active, not recruiting
NCT02186509 Phase I Alisertib Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas Completed
NCT02193347 Phase I Montanide ISA 51 + PEPIDH1M vaccine + Sargramostim + Temozolomide IDH1 Peptide Vaccine for Recurrent Grade II Glioma (RESIST) Active, not recruiting
NCT02238496 Phase II Perifosine + Temsirolimus Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas Active, not recruiting
NCT02273739 Phase Ib/II Enasidenib Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Completed
NCT02303678 Phase I D2C7-IT D2C7 for Adult Patients With Recurrent Malignant Glioma Recruiting
NCT02311582 Phase Ib/II Pembrolizumab MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas Recruiting
NCT02313272 Phase I Bevacizumab + Pembrolizumab Phase I Trial of HFSRT With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas Active, not recruiting
NCT02323880 Phase I Selinexor Study of Selinexor in Pediatric Solid Tumors Active, not recruiting
NCT02330562 Phase I Bevacizumab + Marizomib Study of Marizomib With Bevacizumab in Bevacizumab-Naïve Subjects With WHO Grade IV Malignant Glioma Active, not recruiting
NCT02332889 Phase Ib/II Decitabine Poly ICLC Phase I/II Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs Terminated
NCT02337491 Phase II Pembrolizumab Bevacizumab + Pembrolizumab Pembrolizumab +/- Bevacizumab for Recurrent GBM Completed
NCT02337686 Phase II Pembrolizumab Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma Active, not recruiting
NCT02343718 Phase I Temsirolimus + Vinblastine Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours Completed
NCT02345824 Phase I Ribociclib Early-Phase Study to Assess Inhibitor LEE011 in Patients With Recurrent Glioblastoma or Anaplastic Glioma Unknown status
NCT02358187 Phase II Poly ICLC A Vaccine Trial for Low Grade Gliomas Recruiting
NCT02359565 Phase I Pembrolizumab Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas or Diffuse Intrinsic Pontine Gliomas Recruiting
NCT02366728 Phase II pp65 Dendritic Cell Vaccine + Temozolomide C Migration Study for Newly-Diagnosed GBM (ELEVATE) Active, not recruiting
NCT02372006 Phase Ib/II Afatinib Trial of Afatinib in Pediatric Tumours Active, not recruiting
NCT02390752 Phase Ib/II Pexidartinib PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Recruiting
NCT02423343 Phase Ib/II Galunisertib Nivolumab A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma Completed
NCT02423525 Phase I Afatinib Safety Study of Afatinib for Brain Cancer Active, not recruiting
NCT02455245 Phase III Carboplatin Carboplatin + Vincristine Sulfate A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma Recruiting
NCT02481154 Phase I AG-881 Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation Active, not recruiting
NCT02502708 Phase I Indoximod Temozolomide Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors Completed
NCT02507583 Phase I IGF-1R/AS ODN Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma Active, not recruiting
NCT02525692 Phase II ONC201 Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma Recruiting
NCT02529072 Phase I Nivolumab Nivolumab With DC Vaccines for Recurrent Brain Tumors Completed
NCT02540161 Phase II SYM004 Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma Completed
NCT02549833 Phase I GBM6-AD lysate protein vaccine + Poly ICLC Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma Recruiting
NCT02607124 Phase Ib/II Ribociclib Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) Unknown status
NCT02639546 Phase Ib/II Cobimetinib Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi) Active, not recruiting
NCT02644291 Phase I Mebendazole Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors Recruiting
NCT02644460 Phase I Abemaciclib Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Recruiting
NCT02655601 Phase Ib/II BMX-001 + Temozolomide Temozolomide Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Recruiting
NCT02658279 Phase I Pembrolizumab Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype Recruiting
NCT02659800 Phase I Dexamethasone + NT-I7 Dexamethasone Study of the Effect IL 7/ NT-I7 on CD4 Counts in Patients With High Grade Gliomas Recruiting
NCT02661282 Phase Ib/II Autologous CMV-specific CTLs + Temozolomide Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma Active, not recruiting
NCT02669173 Phase I Bevacizumab + Capecitabine Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma Recruiting
NCT02684058 Phase II Dabrafenib + Trametinib Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG Recruiting
NCT02743078 Phase II Bevacizumab Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma Terminated
NCT02768389 Phase I Bevacizumab Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Completed
NCT02794883 Phase II Tremelimumab Durvalumab + Tremelimumab Durvalumab Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma Active, not recruiting
NCT02829931 Phase I Nivolumab Hypofractionated Stereotactic Irradiation With Nivolumab in Patients With Recurrent High Grade Gliomas Recruiting
NCT02833701 Phase I Bevacizumab Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma Terminated
NCT02840409 Phase II Vinblastine Bevacizumab + Vinblastine Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG) Recruiting
NCT02852655 Phase 0 Pembrolizumab A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma Active, not recruiting
NCT02859857 Phase I BXQ-350 Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors Active, not recruiting
NCT02871843 Phase I RRx-001 + Temozolomide Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1) Active, not recruiting
NCT02885324 Phase II Cabozantinib Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children Recruiting
NCT02924038 Phase I IMA950 + Poly ICLC Varlilumab A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) Recruiting
NCT02933736 Phase 0 Ribociclib Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients Recruiting
NCT02960230 Phase Ib/II H3.3K27M peptide vaccine + Montanide ISA 51 + Nivolumab + Poly ICLC + Tetanus Toxoid peptide H3.3K27M peptide vaccine + Montanide ISA 51 + Poly ICLC + Tetanus Toxoid peptide H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas Recruiting
NCT02968940 Phase II Avelumab Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma Completed
NCT02977689 Phase II IDH305 Trial of IDH305 in IDH1 Mutant Grade II or III Glioma Withdrawn
NCT02986178 Phase II Lomustine + PVSRIPO PVSRIPO PVSRIPO With/Without Lomustine Active, not recruiting
NCT03072134 Phase I NSC-CRAd-Survivin-pk7 Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma Completed
NCT03095248 Phase II Selumetinib Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting
NCT03130959 Phase II Ipilimumab + Nivolumab Nivolumab An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908) Active, not recruiting
NCT03134131 Expanded access ONC201 Expanded Access Program for ONC201 to Treat Recurrent Histone H3 Mutant Glioma Temporarily not available
NCT03173950 Phase II Nivolumab Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers Recruiting
NCT03174197 Phase Ib/II Atezolizumab + Temozolomide Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM) Active, not recruiting
NCT03210714 Phase II Erdafitinib Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Recruiting
NCT03212274 Phase II Olaparib Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Recruiting
NCT03213678 Phase II LY3023414 PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Recruiting
NCT03220646 Phase II Abemaciclib The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors. Recruiting
NCT03233204 Phase II Olaparib Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Recruiting
NCT03245151 Phase Ib/II Everolimus + Lenvatinib Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors Recruiting
NCT03283631 Phase I EGFR-vIII CAR-T Cells Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM Suspended
NCT03295396 Phase II ONC201 ONC201 in Adults With Recurrent H3 K27M-mutant Glioma Recruiting
NCT03352427 Phase II Dasatinib + Everolimus Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring PDGFR Alterations Recruiting
NCT03355794 Phase I Everolimus + Ribociclib A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) Active, not recruiting
NCT03387020 Phase I Ribociclib Everolimus + Ribociclib Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors Completed
NCT03389230 Phase I HER2 CAR-T cells Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma Recruiting
NCT03416530 Phase I ONC201 ONC201 in Pediatric H3 K27M Gliomas Recruiting
NCT03426891 Phase I Pembrolizumab + Temozolomide + Vorinostat Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma Recruiting
NCT03452930 Phase I Tinostamustine Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma Recruiting
NCT03463265 Phase II Lomustine + Nab-Rapamycin Nab-Rapamycin Nab-Rapamycin + Temozolomide Bevacizumab + Nab-Rapamycin ABI-009 (Nab-Rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma Recruiting
NCT03514069 Phase I Ruxolitinib Ruxolitinib + Temozolomide Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma Recruiting
NCT03557359 Phase II Nivolumab Nivolumab for Recurrent or Progressive IDH Mutant Gliomas Recruiting
NCT03581292 Phase II Temozolomide + Veliparib Veliparib Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations Recruiting
NCT03598244 Phase I Savolitinib Volitinib in Treating Participants With Recurrent or Refractory Primary CNS Tumors Recruiting
NCT03605550 Phase I PTC596 A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma Recruiting
NCT03632317 Phase II Everolimus + Panobinostat A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas Withdrawn
NCT03652545 Phase I MultiTAA-specific T cells Multi-antigen T Cell Infusion Against Neuro-oncologic Disease (REMIND) Recruiting
NCT03684811 Phase Ib/II Cisplatin + Gemcitabine + Olutasidenib Azacitidine + Olutasidenib Olutasidenib Nivolumab + Olutasidenib A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation Active, not recruiting
NCT03687957 Phase Ib/II Radiotherapy + Temozolomide NT-I7 + Radiotherapy + Temozolomide rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-lymphopenic Gliomas Following Radiation and Temzolomide Recruiting
NCT03690869 Phase Ib/II Cemiplimab REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma Recruiting
NCT03696355 Phase I GDC-0084 Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas Active, not recruiting
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting
NCT03718767 Phase II Nivolumab Nivolumab in People With IDH-Mutant Gliomas With and Without Hypermutator Phenotype Recruiting
NCT03746080 Phase II Plerixafor + Temozolomide Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma Recruiting
NCT03749187 Phase I Pamiparib + Temozolomide BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PNOC017) Recruiting
NCT03763396 Phase I Posaconazole Ketoconazole Azoles Targeting Recurrent High Grade Gliomas Recruiting
NCT03834740 Phase I Everolimus + Ribociclib A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection Recruiting
NCT03893487 Phase I CUDC-907 Fimepinostat in Treating Brain Tumors in Children and Young Adults (PNOC016) Recruiting
NCT03914742 Phase Ib/II Pamiparib + Temozolomide BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations Recruiting
NCT03919071 Phase II Dabrafenib + Trametinib Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma Recruiting
NCT03922555 Phase I ASTX727 ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas Recruiting
NCT03973879 Phase Ib/II Atezolizumab + PVSRIPO Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma Withdrawn
NCT03973918 Phase II Binimetinib + Encorafenib Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (BRAF) Recruiting
NCT04015700 Phase I GNOS-PV01 + INO-9012 + Ipilimumab + Nivolumab GNOS-PV01 + INO-9012 + Nivolumab Neoantigen-based Personalized DNA Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma Recruiting
NCT04047706 Phase I BMS-986205 + Nivolumab BMS-986205 + Nivolumab + Temozolomide Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Recruiting
NCT04051606 Phase II Regorafenib Phase II Study of Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma Recruiting
NCT04089449 Phase I PRT811 A Study of PRT811 in Participants With Advanced Solid Tumors, Gliomas and Myelofibrosis Recruiting
NCT04099797 Phase I C7R-GD2.CART cells Cyclophosphamide + Fludarabine C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) Recruiting
NCT04160494 Phase I Atezolizumab + D2C7-IT D2C7-IT With Atezolizumab for Recurrent Gliomas Recruiting
NCT04166409 Phase III Selumetinib Carboplatin + Vincristine Sulfate A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma Recruiting
NCT04172597 Phase II Poziotinib A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies Recruiting
NCT04195139 Phase II Nivolumab + Temozolomide Temozolomide Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM (NUTMEG) Recruiting
NCT04201457 Phase Ib/II Hydroxychloroquine + Trametinib Dabrafenib + Hydroxychloroquine + Trametinib A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration Recruiting
NCT04214392 Phase I Chlorotoxin-CD28-CD3z-CD19t CART cells Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of Recurrent or Progressive Glioblastoma Recruiting
NCT04220892 Phase I Abemaciclib + Pembrolizumab Pembrolizumab + Pemetrexed Disodium Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma Withdrawn
NCT04254419 Phase I Intra-tumoral Injection of Natural Killer Cells in High-Grade Gliomas Not yet recruiting
NCT04295759 Phase I INCB7839 INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas Recruiting
NCT04323046 Phase I Ipilimumab Ipilimumab + Nivolumab Nivolumab Immunotherapy (Nivolumab and Ipilimumab) Before and After Surgery for the Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults Not yet recruiting
NCT04334863 Phase I WP1066 AflacST1901: Peds WP1066 Recruiting
NCT04391595 Phase I Abemaciclib + LY3214996 LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients Recruiting
NCT04424966 Phase 0 Infigratinib Infigratinib in Recurrent Glioblastoma Patients Recruiting
NCT04465643 Phase I Ipilimumab + Nivolumab Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor Not yet recruiting
NCT04485559 Phase I Everolimus + Trametinib Trametinib and Everolimus for the Treatment of Pediatric and Young Adult Patients With Recurrent Low Grade Gliomas (PNOC021) Not yet recruiting